HZNP News Alert Horizon Pharma Inc (HZNP) 12.38 12/25/2014 1

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Horizon Pharma Inc (HZNP) 12.38 $HZNP

Horizon Pharma plc Files Patent Infringement Lawsuit Against Watson Laboratories, Inc. for Filing an ANDA Against PENNSAID(R) 2%
Marketwired - Wed Dec 24, 12:00PM CST
Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company with a portfolio of products in arthritis, inflammation and orphan diseases, announced today that the Company has filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Watson Laboratories, Inc. ("WLF" and certain of its affiliated companies, Actavis, plc, and Actavis Inc., related to an Abbreviated New Drug Application ("ANDA" that WLF filed with the U.S. Food and Drug Administration ("FDA" to market a generic version of PENNSAID(R) (diclofenac sodium topical solution) 2% w/w ("PENNSAID 2%" .
HZNP: 12.38 (+0.13)

5 Best Performing Stocks of the Nasdaq in 2014 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 9:58AM CST
The tech-laden Nasdaq Composite index enjoyed a bull run this year banking on broad based gains among Internet and bio-tech stocks, better-than expected GDP numbers and Fed's assurance about the economy.
CMRX: 36.80 (+0.70), SWKS: 74.32 (+0.92), IBM: 161.82 (-0.42), CHL: 59.15 (-0.02), HZNP: 12.38 (+0.13), TKMR: 13.97 (+0.14), GOOGL: 536.93 (-1.84), MSFT: 48.14 (-0.31), AAPL: 112.01 (-0.53), PLNR: 7.04 (-0.15), AVGO: 100.72 (-0.06), RFMD: 16.59 (+0.29)

Cheap Stocks for 2015: The Best Buys in Healthcare
Todd Campbell, The Motley Fool - Motley Fool - Wed Dec 10, 9:33AM CST
Source: Cigna. Healthcare has been one of the best-performing sectors in 2014, and investors are right to question whether stocks in the industry  will continue their winning ways in 2015. While increasing share prices have made many healthcare...
CI: 104.23 (-0.08), GILD: 91.29 (+1.84), CYH: 55.36 (+0.37), HZNP: 12.38 (+0.13), TEVA: 57.09 (+0.33)

Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance
PR Newswire - Wed Nov 26, 7:35AM CST
Investor-Edge has initiated coverage on the following equities: VIVUS Inc. (NASDAQ:VVUS), Horizon Pharma PLC (NASDAQ: HZNP), Endocyte Inc. (NASDAQ: ECYT), Johnson and Johnson (NYSE: JNJ), and Theravance Inc. (NASDAQ: THRX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, November 25, 2014, the NASDAQ Composite ended at 4,758.25, up 0.07%, the Dow Jones Industrial Average edged 0.02% lower, to finish the day at 17,814.94, and the S&P 500 closed at 2,067.03, down 0.12%. During the session, five out of ten sectors ended in positive. The S&P 500 Health Care Sector Index ended the day at 793.40, up 0.07%, with the index also advancing 8.30% in the previous three months. Register for your complimentary reports on these five stocks at:
JNJ: 104.59 (+0.31), ECYT: 6.33 (+0.24), HZNP: 12.38 (+0.13), VVUS: 2.99 (-0.02), THRX: 14.55 (+0.22)

InsiderInsights.com Daily Round Up 11/20/14: NES, OPK, OKS, PAH
InsiderInsights - at Seeking Alpha - Mon Nov 24, 2:04PM CST

NES: 4.96 (-0.44), RAX: 48.24 (+0.45), JAH: 47.91 (+0.10), LNG: 71.64 (-0.12), MRD: 18.64 (-0.53), PAH: 23.00 (+0.01), AON: 96.52 (-0.15), SGM: 12.35 (+0.05), CLI: 19.06 (-0.03), CNCE: 11.76 (+0.11), VSAR: 22.25 (-0.11), OPK: 9.63 (+0.21), HZNP: 12.38 (+0.13), CATY: 25.60 (+0.09), IMH: 6.25 (-0.06), OKS: 41.05 (-0.04), GRPN: 7.89 (-0.14), SFXE: 4.42 (+0.04), SCHW: 30.67 (+0.01)

Horizon Pharma plc to Present at the 26th Annual Piper Jaffray Healthcare Conference
Marketwired - Mon Nov 24, 7:01AM CST
Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company with a portfolio of products in arthritis, inflammation and orphan diseases, today announced that Robert F. Carey, executive vice president and chief business officer, and Paul W. Hoelscher, executive vice president and chief financial officer, will present at the 26th Annual Piper Jaffray Healthcare Conference on Wednesday, December 3, 2014 at 1:30 p.m. Eastern Time in New York, NY.
HZNP: 12.38 (+0.13)

Horizon Pharma plc Announces Presentation of Data Showing Unmet Need in Rheumatoid Arthritis and the Positive Effect of RAYOS(R) (Prednisone) Delayed-Release Tablets in Reducing Joint Stiffness of RA Throughout the Day
Marketwired - Wed Nov 19, 3:44PM CST
Horizon Pharma plc (NASDAQ: HZNP) today announced the presentation of data from five abstracts that review unmet needs in rheumatoid arthritis ("RA" , that support the role of RAYOS(R) (prednisone) delayed-release tablets ("RAYOS" in reducing joint stiffness throughout the day and demonstrate the efficacy of VIMOVO(R) (naproxen/esomeprazole magnesium) ("VIMOVO" in reducing pain in knee osteoarthritis. The data were presented at the American College of Rheumatology (ACR) and Association of Rheumatology Health Professionals (ARHP) Annual Scientific Meeting (ACR/ARHP) in Boston, MA from November 14 through November 19.
HZNP: 12.38 (+0.13)

InsiderInsights.com Daily Round Up 11/17/14: SFM, INTX, GNRC, GSAT
InsiderInsights - at Seeking Alpha - Tue Nov 18, 5:55AM CST

HCOM: 27.34 (+0.27), IPHI: 15.51 (-0.01), JBHT: 84.91 (-0.02), COV: 103.35 (+0.57), OPHT: 44.93 (+1.06), COP: 70.13 (-0.92), SFM: 32.70 (+0.02), GOOG: 528.77 (-1.82), GSAT: 2.97 (+0.03), STAY: 19.60 (-0.31), ZOES: 29.59 (+1.08), INTX: 3.83 (-0.03), GNRC: 47.26 (-0.24), HZNP: 12.38 (+0.13), TRUE: 23.50 (+0.31)

Horizon Pharma discloses pricing of secondary offering of 11.66m ordinary shares
M2 - Mon Nov 17, 6:04AM CST
Biopharmaceutical company Horizon Pharma (NasdaqGS:HZNP) said on Friday that it has priced a secondary public offering of 11,660,445 of its ordinary shares.
HZNP: 12.38 (+0.13)

Horizon Pharma: A Strong Buy Following The Q3 Report
ONeil Trader - at Seeking Alpha - Sat Nov 15, 8:39AM CST

HZNP: 12.38 (+0.13)

Horizon Pharma plc Announces Pricing of Secondary Offering of Ordinary Shares by Selling Shareholders
Marketwired - Fri Nov 14, 7:03AM CST
Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company with a portfolio of products in arthritis, inflammation and orphan diseases, today announced the pricing of a previously announced underwritten secondary offering of 11,660,445 of its ordinary shares held by certain of its existing shareholders, offered at a price to the public of $12.05 per share. Horizon Pharma plc is not issuing new ordinary shares and will not receive any proceeds from the sale of ordinary shares by the selling shareholders in the offering. The offering is expected to close on or about November 19, 2014, subject to customary closing conditions.
HZNP: 12.38 (+0.13), MS: 38.81 (-0.14)

Strong Earnings And Low Valuation To Catalyze Horizon Pharma
David Zanoni - at Seeking Alpha - Thu Nov 13, 8:30AM CST

HZNP: 12.38 (+0.13)

Horizon Pharma plc Announces Proposed Secondary Offering of Ordinary Shares by Selling Shareholders
Marketwired - Thu Nov 13, 6:03AM CST
Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company with a portfolio of products in arthritis, inflammation and orphan diseases, today announced a proposed underwritten secondary offering of 11,660,445 of its ordinary shares held by certain of its existing shareholders. Horizon Pharma plc is not issuing new ordinary shares and will not receive any proceeds from the sale of ordinary shares by the selling shareholders in the offering.
HZNP: 12.38 (+0.13), MS: 38.81 (-0.14)

Horizon Pharma plc Announces Clinical Data on RAYOS(R) (Prednisone) Delayed-Release Tablets and VIMOVO(R) (Naproxen/Esomeprazole Magnesium) to Be Presented at the American College of Rheumatology Annual Meeting
Marketwired - Wed Nov 12, 3:09PM CST
Horizon Pharma plc (NASDAQ: HZNP) today announced that four abstracts related to RAYOS (prednisone) delayed-release tablets and one abstract on VIMOVO (naproxen/esomeprazole magnesium) will be presented during the American College of Rheumatology (ACR) and Association of Rheumatology Health Professionals (ARHP) Annual Scientific Meeting taking place November 15 to 19, 2014 in Boston, MA.
HZNP: 12.38 (+0.13)

Horizon Pharma plc Announces Favorable Markman Ruling in RAYOS(R) (prednisone) Delayed-Release Tablets Patent Infringement Litigation
Marketwired - Wed Nov 12, 7:05AM CST
Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company with a portfolio of products in arthritis, inflammation and orphan diseases, today announced that a favorable Markman ruling has been issued by Judge Joseph E. Irenas of the United States District Court for the District of New Jersey in the patent infringement lawsuit filed by Horizon against Watson Laboratories, Inc. for an Abbreviated New Drug Application ("ANDA" to market a generic version of RAYOS.
HZNP: 12.38 (+0.13)

Horizon Pharma plc to Present at the Stifel 2014 Healthcare Conference
Marketwired - Tue Nov 11, 3:05PM CST
Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company with a portfolio of products in arthritis, inflammation and orphan diseases, today announced that Robert F. Carey, executive vice president and chief business officer, will present at the Stifel 2014 Healthcare Conference on Tuesday, November 18, 2014 at 4:45 p.m. Eastern Time in New York, NY. Mr. Carey will provide an overview of the Company and its corporate activities.
HZNP: 12.38 (+0.13)

Horizon Pharma's (HZNP) CEO Timothy Walbert on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 12:20PM CST

HZNP: 12.38 (+0.13)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 8:14AM CST

ACAS: 14.95 (+0.12), WWWW: 19.23 (-0.03), PHMD: 1.46 (-0.03), RVLT: 1.28 (-0.02), SNMX: 5.95 (+0.34), PBR: 7.60 (-0.11), QCOM: 74.66 (+0.06), GNRC: 47.26 (-0.24), HZNP: 12.38 (+0.13), PESI: 4.38 (unch), WAC: 16.73 (-0.15), TRUE: 23.50 (+0.31), KATE: 29.83 (+0.44), DRYS: 1.20 (-0.04), Z: 104.60 (-0.16), WFM: 48.67 (-0.40), SWIR: 47.29 (+0.13), COT: 6.90 (-0.03), CSOD: 36.66 (-0.14), MCP: 0.72 (+0.01), GNW: 8.40 (+0.01), CECO: 6.72 (+0.09), GERN: 3.06 (+0.05), NDLS: 25.88 (+0.20), MEET: 1.51 (unch), AEZS: 0.59 (-0.02), DATA: 88.76 (+0.04), PLNR: 7.04 (-0.15), SZYM: 2.70 (+0.04)

Horizon Pharma elects John J. Kody as EVP
M2 - Thu Nov 06, 7:22AM CST
Biopharmaceutical company Horizon Pharma (NasdaqGS:HZNP) said on Thursday that its board has named John J. Kody as its executive vice president and chief commercial officer, as well as to its executive committee.
HZNP: 12.38 (+0.13), DHR: 86.79 (-0.27)

Horizon Pharma (HZNP) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Nov 06, 6:55AM CST

HZNP: 12.38 (+0.13)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

ECW Puts $52 Million Behind Learning Through Crisis

Updated Category News Views 66

A reserve fund for a classroom is not glamorous, but it may be the smartest detail in this whole $52 million commitment. Education Cannot Wait has announced support for more than 300,000 children in Lebanon, Myanmar and South Sudan, where war, flooding and displacement have ripped ordinary schooling apart. The money is meant to restore learning, provide catch-up classes...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 22

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
YYForce Security Win Adds Recurring Singapore Revenue Base

Updated Category News Views 160

A retail-property security mandate rarely makes anyone pound the table, and frankly it should not. Still, YYForce has landed a tangible two-year contract in Singapore worth roughly S$831,120, with subsidiary Uniforce Security Services set to begin work on December 1, 2026. For NASDAQ:YFOR investors, this is the kind of small, operationally real win that deserves a sober...

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 58

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading
Niron's $1.8B Alabama Bet Carries Big Magnet Stakes

Updated Category News Views 54

A Huge Factory Claim Needs More Than Applause A magnet company just tossed a very large number onto Alabama's economic-development table. Niron Magnetics says it plans a $1.8 billion investment in the state that would create 700 jobs. That is not pocket change, not a ribbon-cutting trinket, and not the sort of announcement investors should breeze past between earnings...

Continue Reading
Appian Survey Flags AI Aloneware Maintenance Drag Risk

Updated Category News Views 58

A bot can spit out a feature before lunch, then leave a repair bill nobody budgeted for. That is the uncomfortable issue behind Appian's new research on AI-assisted software development: speed is easy to celebrate, while ownership gets shoved into a dark corner until something breaks. Appian said on November 20, 2026, that two-thirds of surveyed AI decision-makers and IT...

Continue Reading
Sogroya Approval Broadens Novo's Pediatric Growth Franchise

Updated Category News Views 75

Seven fewer injections every week is the real headline behind Novo Nordisk's latest FDA clearance, not some flashy efficacy leap. On November 20, 2026, the company said Sogroya, its once-weekly long-acting growth hormone, won approval for children aged 2.5 and older with growth failure associated with Turner syndrome. That matters because treatment can stretch over years,...

Continue Reading
PCS Rental Prep Is About Control Before Distance Hits

Updated Category News Views 82

A vacant house can turn into a long-distance headache with startling speed. For military homeowners preparing for a PCS move, the useful point in Rhonda Leahy's guidance is not glamorous: settle the boring operational stuff before the moving boxes, travel orders, and new-duty-station chaos swallow the calendar. Renting out a former home is not merely collecting enough...

Continue Reading
Mobile Core's Cost Crunch Favors Telecom's Big Three

Updated Category News Views 67

Server bills have finally crashed the party in mobile core, and nobody should pretend that is a minor inconvenience. Dell'Oro Group's 3Q 2026 read is blunt: Mobile Core Network revenue growth was lackluster because 5G spending came in below expectations, while higher server costs pushed operators to reshuffle priorities, postpone projects, and keep 4G core gear alive...

Continue Reading
Why Brief Chiropractic Visits Still Need Clear Expectations

Updated Category News Views 76

A few minutes on the table can sound almost suspiciously brisk when somebody is dealing with a stiff neck, sore back, or nagging joint discomfort. Yet that is the central point in Dr. Craig Peterson's explanation for HelloNation: the adjustment itself may be brief, while the value of a chiropractor visit depends on a focused assessment, appropriate technique, and whether...

Continue Reading

Top 5 Most Recently Viewed Articles

Organon & Co. Class Action Lawsuit: Key Details You Should Know

Updated Category News Views 221

Overview of the Class Action Lawsuit Against Organon & Co. The latest developments in the class action lawsuit regarding Organon & Co. (NYSE: OGN) have attracted attention from investors. The lawsuit is aimed at representing purchasers of Organon's publicly traded securities during a specific time frame. Robbins Geller Rudman & Dowd LLP has taken the lead in filing this...

Continue Reading
JINRO Partners with BTS's V: A Strategic Move

Updated Category News Views 25

What's Brewing Between JINRO and BTS's V? Picture this: you're wandering the aisles of an international market, see a splashy new bottle of soju, and notice V from BTS smiling from the label. That's right, folks, JINRO, the world's reigning soju brand, has just snagged a partnership with BTS's V to serve up a global brand punch. This move isn't just a pretty face on a...

Continue Reading
Latin Metals Unveils Exciting Spin-Out Plan for Copper Assets

Updated Category News Views 172

Latin Metals Moves Forward with Spin-Out of Peruvian Assets Latin Metals Inc. (TSXV: LMS, OTCQB: LMSQF) is charting a new course by announcing its decision to spin-out certain Peruvian exploration projects into a newly founded subsidiary named Latin Explore. This strategic move aims to unlock value for shareholders while maintaining a robust exploration agenda. Overview...

Continue Reading
McCormick's Resilience Shines Amidst Economic Challenges

Updated Category News Views 66

McCormick Challenges and Growth Strategy McCormick & Company, Inc. (NASDAQ: MKC) recently announced its third-quarter earnings, revealing a solid financial performance, even in a tough consumer environment. The company achieved a 1% volume growth in its Consumer segment and steady sales in its Flavor Solutions segment, showcasing a strong market presence despite...

Continue Reading
Goodyear's Financial Performance Amidst Industry Challenges

Updated Category News Views 248

Understanding Goodyear's Recent Earnings Report Goodyear Tire & Rubber Co (NASDAQ: GT) has reported its recent financial results, particularly highlighting the challenges faced during the second quarter of their fiscal year 2025. This period proved to be quite turbulent after the closing bell, reflecting considerable disruptions in their operating environment that...

Continue Reading